Oct 04, 2023 / 12:00PM GMT
Mark Andrew Rothera - Viracta Therapeutics, Inc. - CEO, President & Director
Welcome to Viracta's R&D Day, both to everyone here in the room in New York, but also to those joining us remote. Viracta, for some of you who may not know Viracta so well, we were founded in 2015, and our mission is to treat and prevent virus-associated cancers. And you'll see that today, our focus is going to be on our lead program, Nana-val, which is an all-oral combination of nanatinostat and valganciclovir, and we will hear more about that in a minute.
So for those of you who don't know me, my name is Mark Rothera. I've been 33 years in the biopharmaceutical industry. I have been CEO of Viracta for the last year. And really during my career, I've been fortunate to help build and lead the build of 6 previous biotech companies and now Viracta the 7th. And in that journey, my primary purpose has been to bring to the world's meaningful medicines for rare and specialized diseases. And that's why I joined Viracta because I think that Nana-val represents a medicine at the intersection of oncology and rare disease.
Viracta Therapeutics Inc To Host R&D Day Transcript
Mar 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers